NCT01574638View on ClinicalTrials.gov

Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Tuberculosis
Interventions
DRUG

Rifapentine (RPT)

Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.

Trial Locations (4)

21205

Johns Hopkins University CRS, Baltimore

27599

Chapel Hill CRS, Chapel Hill

37204

Vanderbilt Therapeutics (VT) CRS, Nashville

92103

UCSD Antiviral Research Center CRS, San Diego

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01574638 - Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults | Biotech Hunter | Biotech Hunter